Loading people...
Avital Adler is a Principal at Arkin Bio Ventures based in Israel, where she focuses on Seed and Series A investments in the biotechnology and diagnostics sectors. Prior to assuming this role in 2025, she spent four years at the venture capital firm aMoon, leading scientific and business due diligence for private biotech investments. During her tenure at aMoon, she also played a key role in establishing aMoon Edge, the firm's public markets investment platform. Before transitioning to venture capital, Adler completed a postdoctoral fellowship at NYU Medical Center and earned a doctorate in neural computation from Hebrew University. Her academic research career yielded 21 peer-reviewed publications in scientific journals such as Nature Neuroscience and Neuron. She applies her extensive academic foundation in neuroscience to identify and support early-stage life sciences companies across the private and public markets.
Avital Adler is an integral Analyst at aMoon Fund, a globally recognized venture capital firm committed to revolutionizing healthcare through strategic investments. At aMoon Fund, Avital contributes to the rigorous process of sourcing, evaluating, and supporting early to growth stage companies that are developing cutting-edge solutions in health tech and life sciences.
aMoon Fund is known for its deep expertise and focus on the healthcare sector, aiming to bridge the gap between scientific discovery and market-ready solutions. Avital's role as an Analyst is critical in this mission, involving comprehensive market research, due diligence, and financial analysis to assess potential investment opportunities. She works closely with the investment team to identify companies that not only demonstrate strong technological innovation but also possess the potential for significant market impact and scalability.
Her investment focus areas align with aMoon Fund's broader strategy, encompassing a wide range of healthcare innovations. This includes digital health platforms, medical devices, biotechnology, pharmaceuticals, and other disruptive technologies designed to improve patient outcomes, enhance healthcare efficiency, and reduce costs. Avital's analytical skills are vital in dissecting complex scientific and market data to uncover promising ventures that align with the fund's investment thesis.
While specific notable investments led by Avital Adler as an Analyst are part of the fund's collective strategy, her contributions are fundamental to the overall success of aMoon's portfolio. She supports the fund's efforts to back companies that are at the forefront of medical breakthroughs and technological advancements, helping to shape the future of healthcare.
Avital's career background likely reflects a strong foundation in science, finance, or a related analytical field, coupled with a genuine passion for healthcare innovation. Her expertise allows her to delve into the intricacies of new medical technologies and business models, providing valuable insights to the investment committee. Through her dedicated work at aMoon Fund, Avital Adler is actively involved in empowering the next generation of healthcare leaders and innovators, driving progress in a sector vital to global well-being.
Avital Adler is an Analyst at aMoon Fund, a venture capital firm focused on health technology and life sciences investments. She plays a key role in evaluating and supporting innovative healthcare companies.
As an Analyst at aMoon Fund, Avital Adler contributes to investments in a broad range of health tech and life sciences areas, including digital health, medical devices, biotechnology, and pharmaceuticals.
Avital Adler works as an Analyst at aMoon Fund, a leading venture capital firm specializing in healthcare innovation.
